Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR) α-selective agonists

Bioorg Med Chem. 2011 May 15;19(10):3183-91. doi: 10.1016/j.bmc.2011.03.064. Epub 2011 Apr 8.

Abstract

A series of α-ethylphenylpropanoic acid derivatives was prepared as candidate peroxisome proliferator-activated receptor (PPAR) α-selective agonists, based on our PPARα/δ dual agonist 3 as a lead compound. Structure-activity relationship studies clearly indicated that the steric bulkiness and position of the distal hydrophobic tail part are critical for PPARα agonistic activity and PPARα selectivity, as had been predicted from a molecular-modeling study. A representative compound blocked the progression of nonalcoholic steatohepatitis (NASH) in an animal model.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Drug Design
  • Fatty Liver / prevention & control
  • Humans
  • Male
  • Models, Molecular
  • Non-alcoholic Fatty Liver Disease
  • PPAR alpha / agonists*
  • PPAR alpha / metabolism
  • Phenylpropionates / chemical synthesis
  • Phenylpropionates / chemistry*
  • Phenylpropionates / pharmacology
  • Phenylpropionates / therapeutic use*
  • Rats
  • Rats, Wistar
  • Structure-Activity Relationship

Substances

  • PPAR alpha
  • Phenylpropionates